Home / Research library / FOXO4-DRI
Compound guide
FOXO4-DRI: what the research covers
A deliberately broken copy of a protein interaction surface. Its purpose is not to activate anything but to get in the way of a partnership that keeps senescent cells alive.
What FOXO4-DRI is
Senescent cells are not dead. They have stopped dividing and they secrete an inflammatory signature, but they resist apoptosis, and part of that resistance comes from FOXO4 binding p53 and holding it in the nucleus where it cannot trigger cell death. Break that interaction and p53 is released; in a senescent cell, that is often enough to push it into apoptosis.
FOXO4-DRI is a peptide copy of the FOXO4 region that binds p53, built so that it competes for the interaction without doing FOXO4 job. DRI stands for D-retro-inverso: the sequence is reversed and every residue is in the D configuration, which produces a molecule whose side chains present in approximately the original spatial arrangement while being invisible to proteases that only recognise L-peptides.
It is therefore a competitive interaction inhibitor — not an agonist, not an antagonist at a receptor, but a decoy.
What senolytic means, and what it does not
The published work is preclinical and the headline findings came from aged and progeroid mouse models, where treatment reduced senescent cell burden and improved several functional measures. That is a striking result and it helped establish senolytics as a field. It is also a mouse result, obtained with a specific preparation, and it has not been reproduced in human trials because there have not been any.
The mechanistic literature covers the FOXO4-p53 interaction itself, selectivity for senescent over proliferating cells, and the general question of whether clearing senescent cells is beneficial in every tissue — it is not obviously so, since senescence also functions as a tumour-suppressive and wound-healing mechanism. A laboratory working here should treat tissue specificity as an open question rather than a solved one.
The retro-inverso design is itself a subject of study: whether a reversed all-D peptide truly reproduces the binding surface of the original is sequence-dependent and not guaranteed.
How Amino Club supplies it
Supplied lyophilised in sealed vials as FOXO4-DRI, specified at 99% purity or better by HPLC with identity confirmed by mass spectrometry and released against the Certificate of Analysis for its own batch, as set out on the lab testing page.
An all-D retro-inverso peptide has the same mass as its L-counterpart, so mass spectrometry confirms composition but not stereochemistry — that rests on the synthesis route and on chromatographic behaviour against reference. It also means the molecule is far more stable in solution than an ordinary peptide of the same length, since the proteases that would clear it cannot engage it. Storage is nonetheless below −18 °C for the sealed powder. Diluents are under reconstitution supplies.
Related reading
FOXO4-DRI belongs to the longevity research peptides group with Epithalon, NAD+, MOTS-c, SS-31, Thymalin and Thymosin Alpha-1. The four hypotheses those compounds test are set out on the hub page.
Every guide is indexed in the research library. Certificates and storage are covered on the FAQ, quantity pricing through bulk and wholesale.
Research use only
FOXO4-DRI supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.